The 36-month beta value for AQST is also noteworthy at 2.90. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for AQST is 79.79M, and at present, short sellers hold a 2.85% of that float. The average trading volume of AQST on April 16, 2024 was 2.31M shares.
AQST) stock’s latest price update
Aquestive Therapeutics Inc (NASDAQ: AQST) has experienced a decline in its stock price by -2.94 compared to its previous closing price of 3.94. However, the company has seen a fall of -6.50% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-12 that WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced a poster presentation highlighting the crossover study for the Company’s product candidate, Libervant™ (diazepam) Buccal Film for treatment of children with epilepsy aged two to five, will be presented at the 76th Annual Meeting of the American Academy of Neurology (AAN) in Denver from April 13 to 18, offering both in-person attendance and live online participation in a hybrid format.
AQST’s Market Performance
Aquestive Therapeutics Inc (AQST) has seen a -6.50% fall in stock performance for the week, with a -37.21% decline in the past month and a 44.03% surge in the past quarter. The volatility ratio for the week is 6.83%, and the volatility levels for the past 30 days are at 8.22% for AQST. The simple moving average for the past 20 days is -10.86% for AQST’s stock, with a 62.37% simple moving average for the past 200 days.
Analysts’ Opinion of AQST
Many brokerage firms have already submitted their reports for AQST stocks, with Piper Sandler repeating the rating for AQST by listing it as a “Overweight.” The predicted price for AQST in the upcoming period, according to Piper Sandler is $10 based on the research report published on April 11, 2024 of the current year 2024.
Raymond James, on the other hand, stated in their research note that they expect to see AQST reach a price target of $7. The rating they have provided for AQST stocks is “Outperform” according to the report published on March 28th, 2024.
RBC Capital Mkts gave a rating of “Outperform” to AQST, setting the target price at $7 in the report published on April 07th of the previous year.
AQST Trading at -1.57% from the 50-Day Moving Average
After a stumble in the market that brought AQST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.62% of loss for the given period.
Volatility was left at 8.22%, however, over the last 30 days, the volatility rate increased by 6.83%, as shares sank -30.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +44.68% upper at present.
During the last 5 trading sessions, AQST fell by -6.97%, which changed the moving average for the period of 200-days by +139.31% in comparison to the 20-day moving average, which settled at $4.20. In addition, Aquestive Therapeutics Inc saw 89.31% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AQST starting from Schobel Alexander Mark, who sale 50,000 shares at the price of $6.00 back on Mar 15 ’24. After this action, Schobel Alexander Mark now owns 984,476 shares of Aquestive Therapeutics Inc, valued at $300,000 using the latest closing price.
Schobel Alexander Mark, the Chief Innovation/Tech Officer of Aquestive Therapeutics Inc, sale 25,000 shares at $5.19 during a trade that took place back on Mar 08 ’24, which means that Schobel Alexander Mark is holding 1,040,371 shares at $129,685 based on the most recent closing price.
Stock Fundamentals for AQST
Current profitability levels for the company are sitting at:
- -0.02 for the present operating margin
- 0.59 for the gross margin
The net margin for Aquestive Therapeutics Inc stands at 0.07. The total capital return value is set at -0.02.
Based on Aquestive Therapeutics Inc (AQST), the company’s capital structure generated -7.15 points at debt to capital in total, while cash flow to debt ratio is standing at -0.07. The debt to equity ratio resting at -0.88. The interest coverage ratio of the stock is -0.19.
Currently, EBITDA for the company is -13.54 million with net debt to EBITDA at 253.21. When we switch over and look at the enterprise to sales, we see a ratio of 8.27. The receivables turnover for the company is 5.97for trailing twelve months and the total asset turnover is 0.88. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.24.
Conclusion
In summary, Aquestive Therapeutics Inc (AQST) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
